

ImmuPharma PLC

08:19 26 Jun 2019

ImmuPharma raises around £2.66mIn from subscription agreement with institutional investor, Lanstead Capital

ImmuPharma PLC (LON:IMM) has raised around £2.66mIn from a subscription agreement with institutional investor, Lanstead Capital, together with a related sharing agreement.

The AIM-listed specialist drug discovery and development Company said Lanstead is subscribing for 26,565,200 new ordinary shares at an issue price of 10p each, representing approximately 19% of the company's existing issued share capital. The issue price represents a 26.5% discount to Immupharma's closing mid-market price on Tuesday.

READ: ImmuPharma continuing to talk with potential partners

The subscription, the maximum amount under the company's existing authorisation, represents a further supportive investment in the company by Lanstead following the £4.43mIn it made investment in February 2016, from which the Company ultimately received just over £5.0mIn including the additional funds received through a sharing agreement over time.

The sharing agreement with Lanstead, entitles the company to receive back the proceeds on a pro rata monthly basis over a period of 24 months, subject to adjustment upwards or downwards each month depending on the company's share price at the time.

The group said the sharing agreement provides the opportunity for the company to benefit from positive future share price performance. It has also agreed to issue 1,328,290 ordinary shares to Lanstead in connection with entering into the sharing agreement.

Immupharma said the proceeds of the subscription will be used primarily to fund the execution of its corporate strategy, as announced on 7 May 2019, including progressing Lupuzor through both corporate partnerships and regulatory pathways and proactively pursuing the 'spin-off' of the subsidiary companies, Ureka and ELRO, in order to unlock their future potential and enhance value to shareholders.


Commenting on the share subscription, ImmuPharma's Chairman, Tim McCarthy, said: "Lanstead has been very supportive of the Company since their first investment in 2016 and this latest subscription demonstrates their continued support and the alignment of both the Company and Lanstead's belief of the potential of substantial value enhancement for shareholders in the future execution of the Company's recently stated corporate strategy."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Price: 7.6

Market Cap: £12.72 m

1 Year Share Price Graph



November 2018 May 2019 November 20

Share Information

Code: IMM

Listing: AIM

52 week High Low
18.5 7.32867

Sector: Pharma & Biotech

Website: www.immupharma.co.uk

Company Synopsis:

Developing innovative therapies for specialist diseases

ImmuPharma PLC is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG).

action@proactiveinvestors.com

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).